India's burgeoning market for weight-loss drugs is prompting diagnostic chains to offer specialized health checks, ensuring patient safety and treatment effectiveness. The rising demand for medications like Mounjaro and Wegovy, both belonging to a class of drugs known as GLP-1 receptor agonists, has led to increased medical caution and the need for continuous monitoring.
GLP-1 receptor agonists, including semaglutide and tirzepatide, have rapidly gained popularity in India, becoming a major topic of discussion across various social circles. These drugs, initially designed for Type 2 diabetes, have been extended to treat medically significant obesity. They work by reducing appetite and prolonging the feeling of fullness, helping individuals manage their weight.
Mounjaro, developed by Eli Lilly, has quickly become India's top-selling drug by value, surpassing even the widely used antibiotic Augmentin. In October, Mounjaro generated 1 billion rupees in sales, exceeding Augmentin's 800 million rupees. This rapid growth underscores the increasing demand for weight-loss treatments in the country. Wegovy, from Novo Nordisk, entered the Indian market in June, further fueling the competition in this space.
Thyrocare, a leading diagnostic laboratory chain, has responded to this trend by launching a GLP-1 Health Check. These comprehensive packages include up to 81 tests designed to monitor key health parameters before, during, and after GLP-1 therapy. Priced at Rs 2,799 and available nationwide, these tests aim to provide patients and clinicians with reliable diagnostic insights throughout the treatment process. These checks enable the early detection of side effects, nutritional deficiencies, and shifts in metabolic functions.
Despite the excitement surrounding these drugs, it's crucial to address common misconceptions. Actual weight-loss responses vary significantly, ranging from modest reductions to substantial losses, with some individuals experiencing minimal or no change. The cost of these medications, ranging from Rs 10,000 to Rs 25,000 per month, also places them beyond the reach of many households.
Moreover, the biological effects of GLP-1-based drugs last only while the medication is continued; weight regain is predictable once treatment stops. Therefore, these drugs should not be seen as a quick fix but rather as a long-term treatment option. It is important to note that one loses more than just fat when they lose 10kg.
These drugs offer benefits beyond just weight loss, including reduced risk of heart attack, improved kidney function, and potential cognitive benefits. They can also help reduce snacking and other addictions. Some patients have even avoided knee replacement surgery after losing weight with these medications.
Semaglutide's patent is set to expire in March 2026, which will allow generic versions to enter the market. Over 20 companies are planning to manufacture generic versions, potentially making these drugs more accessible. Researchers are also developing new drugs like retatrutide, which targets multiple hormones for even greater weight loss.
The rise of weight-loss drugs in India represents a significant advancement in obesity and diabetes treatment. However, they must be used correctly, under medical supervision, and avoided for cosmetic or event-driven weight loss. Regular diagnostic checks and a clear understanding of the treatment's long-term implications are essential for ensuring patient safety and maximizing the benefits of these medications.
